Differential inductions of matrix metalloproteinase-2 and -9 in host tissues during the growth of ascitic sarcoma 180 cells in mice

Cancer Letters

Volumn 189, Issue 1, 2003, Pages 103-112

  Kuo, Wu Hsien ^a   Yang, Shun Fa ^b   Chu, Shu Chen ^c   Lu, Shio Ohin ^b   Chou, Fen Pi ^b   Hsieh, Yih Shou ^b  

^a TAICHUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c CHUNGTAI INST HLTH SCI TECHNOL   (Taiwan)

Author keywords

Metalloproteinase; Metastasis; Tissue preference

Indexed keywords

GELATINASE A; GELATINASE B;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES TUMOR; CANCER GROWTH; CANCER TISSUE; CONTROLLED STUDY; ENZYME INDUCTION; LIVER METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA CELL; SPLEEN; ZYMOGRAPHY;

ANIMALS; LIVER; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED ICR; SARCOMA 180; SPLEEN;

EID: 0037427564     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(02)00323-3     Document Type: Article

References (42)

1. Liotta L.A., Steeg P.S., Stetler-Stevenson W.C. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 64:1991;327-336.
2. Hart C.A., Scott L.J., Bagley S., Bryden A.A., Clarke N.W., Lang S.H. Role of proteolytic enzymes in human prostate bone metastasis formation: in vivo and in vitro studies. Br. J. Cancer. 86:2002;1136-1142.
3. Tetu B., Brisson J., Wang C.S., Lapointe H., Beaudry G., Blanchette C. Expression of cathepsin D, stromelysin-3, and urokinase by reactive stromal cells on breast carcinoma prognosis. Cancer. 92:2001;2957-2964.
4. Chambers A.F., Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. 89:1997;1260-1270.
5. Kleiner D.E., Stetler-Stevenson W.G. Matrix metalloproteinases and metastasis. Cancer Chemother. Pharm. 43:(Suppl):1999;S42-S51.
6. Westermarck J., Kahari V.M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 13:1999;781-792.
7. 1 integrins during human melanoma cell invasion. Cancer Res. 53:1993;3411-3415.
8. r 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. Cancer Res. 52:1992;1336-1341.
9. r 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res. 51:1991;439-444.
10. Zucker S., Lysik R.M., Zarrabi M.H., Moll U.M. 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res. 53:1993;140-146.
11. Ura H., Bonfil R.D., Reich R., Reddel R., Pfeifer A., Harris C.C., Klein-Szanto A.J. Expression type IV collagenase and procollagen genes and its correlation with the tumorigenic, invasive, and metastatic abilities of oncogene-transformed human bronchial epithelial cells. Cancer Res. 49:1989;4615-4621.
12. Stearns M.E., Wang M. Type IV collagenase (Mr 72,000) expression in human prostate: Benign and malignant tissue. Cancer Res. 53:1993;878-883.
13. Davies B., Waxman J., Wasan H., Abel P., Williams G., Krausz T., Neal D., Thomas D., Hanby A., Balkwill F. Levels of matrix metalloproteinases in bladder cancer correlate with tumor grade and invasion. Cancer Res. 53:1993;5365-5369.
14. Fidler I.J. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res. 38:1978;2651-2660.
15. Rubin P. Clinical Oncology. 4th Edition: 1974;American Cancer Society, New York.
16. Zuckerberg C. Ultrastructure of sarcoma 180. Cancer Res. 33:1973;2278-2282.
17. Noguchi T., Kashiwagi A., Tanaka T. A factor responsible for increases in ornithine decarboxylase activity in the livers of tumor-bearing mice. Cancer Res. 36:1976;4015-4022.
18. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
19. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
20. Jiang W.G. Cell adhesion molecules in the formation of liver metastasis. J. Hepatobiliary Pancreat. Surg. 5:1998;375-382.
21. Chambers A.F., MacDonald I.C., Schmidt E.E., Morris V.L., Groom A.C. Preclinical assessment of anti-cancer therapeutic strategies using in vivo videomicroscopy. Cancer Metastasis Rev. 17:1999;263-269.
22. Koop S., MacDonald I.C., Luzzi K., Schmidt E.E., Morris V.L., Grattan M., Khokha R., Chambers A.F., Groom A.C. Fate of melanoma cells entering the microcirculation: over 80% survive and extravasate. Cancer Res. 55:1995;520-523.
23. Morris V.L., Koop S., MacDonald I.C., Schmidt E.E., Grattan M., Percy D., Chambers A.F., Groom A.C. Mammary carcinoma cell lines of high and low metastatic potential differ not in extravasation but in subsequent migration and growth. Clin. Exp. Metastasis. 12:1994;357-367.
24. Koop S., Khokha R., Schmidt E.E., MacDonald I.C., Morris V.L., Chambers A.F., Groom A.C. Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res. 54:1994;4791-4797.
25. Wylie S., MacDonald I.C., Varghese H.J., Schmidt E.E., Morris V.L., Groom A.C., Chambers A.F. The matrix metalloproteinases inhibitor batimastat inhibits angiogenesis in liver metastases of B16F1 melanoma cells. Clin. Exp. Metastasis. 17:1999;111-117.
26. Wu J., Akaike T., Hayashida K., Okamoto T., Okuyama A., Maeda H. Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases. Jpn. J. Cancer Res. 92:2001;439-451.
27. Benbow U., Schoenermark M.P., Mitchell T.I., Rutter J.L., Shimokawa K., Nagase H., Brinckerhoff C.E. A novel host/tumor cell interaction activates matrix metalloproteinases 1 and mediates invasion through type I collagen. J. Biol. Chem. 274:1999;25371-25378.
28. Segain J.P., Harb J., Gregoire M., Meflah K., Menanteau J. Induction of fibroblast gelatinase B expression by direct contact with cell lines derived from primary tumor but not from metastases. Cancer Res. 56:1996;5506-5512.
29. Martorana A.M., Zheng G., Crowe T.C., O'Grady R.L., Lyons J.G. Epithelial cells up-regulate matrix metalloproteinases in cells within the same mammary carcinoma that have undergone an epithelial-mesenchymal transition. Cancer Res. 58:1998;4970-4979.
30. Guo H., Zucker S., Gordon M.K., Toole B.P., Biswas C. Stimulation of matrix metalloproteinases production by recombinant extracellular matrix metalloproteinases inducer from transfected Chinese Hamster ovary cells. J. Biol. Chem. 272:1997;24-27.
31. Heppner K.J., Matrisian L.M., Jensen R.A., Rodgers W.H. Expression of most matrix metalloproteinases family members in breast cancer represents a tumor-induced host response. Am. J. Pathol. 149:1996;273-282.
32. Himelstein B.P., Canete-Soler R., Bernhard E.J., Muschel R.J. Induction of fibroblast 92 kDa gelatinase/type IV collagenase expression by direct contact with metastatic tumor cells. J. Cell Sci. 107:1994;477-486.
33. Nakahara W., Fukuoka F. The new concept of caner toxin. Adv. Cancer Res. 5:1958;157-177.
34. Nagakawa Y., Aoki T., Kasuya K., Tsuchida A., Koyanagi Y. Histologic features of venous invasion, expression of vascular endothelial growth factor and matrix metalloproteinase-2 and matrix metalloproteinase-9, and the relation with liver metastasis in pancreatic cancer. Pancreas. 24:2002;169-178.
35. Giannelli G., Bergamini C., Marinosci F., Fransvea E., Quaranta M., Lupo L., Schiraldi O., Antonaci S. Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int. J. Cancer. 97:2002;425-431.
36. Okada N., Ishida H., Murata N., Hashimoto D., Seyama Y., Kubota S. Matrix metalloproteinase-2 and -9 in bile as a marker of liver metastasis in colorectal cancer. Biochem. Biophys. Res. Commun. 288:2001;212-216.
37. Theret N., Musso O., Turlin B., Lotrian D., Bioulac-Sage P., Campion J.P., Boudjema K., Clement B. Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology. 34:2001;82-88.
38. O'Reilly M.S., Wiederschain D., Stetler-Stevenson W.G., Folkman J., Moses M.A. Regulation of angiostatin production by matrix metalloproteinases-2 in a model of concomitant resistance. J. Biol. Chem. 274:1999;29568-29571.
39. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79:1994;315-328.
40. Wu Z., O'Reilly M.S., Folkman J., Shing Y. Suppression of tumor growth with recombinant murine angiostatin. Biochem. Biophys. Res. Commun. 236:1997;651-654.
41. Sim B.K., O'Reilly M.S., Liang H., Fortier A.H., He W., Madsen J.W., Lapcevich R., Nacy C.A. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res. 57:1997;1329-1334.
42. Theret N., Musso O., Campion J.P., Turlin B., Loreal O., L'Helgoualc'h A., Clement B. Overexpression of matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 in liver from patients with gastrointestinal adenocarcinoma and no detectable metastasis. Int. J. Cancer. 74:1997;426-432.